Pharmaxis granted FDA clearance to produce Aridol locally for US market

ASX-listed pharmaceutical company, Pharmaxis has today been granted FDA clearance to commence Sydney-based production of its asthma diagnostic medication, Aridol for the US. The approval follows hot-on-the-heels of the FDA’s recent inspection of the Sydney facility which manufactures Aridol for Australia, South Korea and Europe, and Bronchitol for Australia, Europe and Russia respectively. Following FDA…

Read More

Seqirus to release additional 700,000 adult flu vaccine doses to help boost “community immunity” against preventable infection

Seqirus announced the manufacture of another 500,000 doses of their adult influenza vaccine, Afluria Quad (inactivated quadrivalent influenza vaccine, split virion) today to help meet increasing consumer demand. Having fulfilled the government’s request to re-enter production, Seqirus is now ahead of the National Immunisation Program (NIP) schedule, with its first vaccine set for release this…

Read More

Mundipharma pioneering prostate cancer research in Australia

A Medical Oncologist from Chris O’Brien Lifehouse, Sydney has recently clinched a $60,000 2018 Mundipharma ANZUP Uro-Oncology Clinical Research Fellowship to support her research into prostate cancer. Dr Kate Mahon is the fifth recipient of the annual Clinical Research Fellowship awarded in partnership with the Australian and New Zealand Urogenital and Prostate Cancer Trials Group…

Read More

Childhood depression and obesity link

The most recent childhood obesity data is cause for concern, with almost 28 per cent of Australian children recorded as either overweight or obese in 2014-15. A recent meta-analysis of more than 51,000 study participants has revealed a positive link between childhood and adolescent obesity and depression. Australian kids who are overweight and obese are…

Read More